Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease

Journal of Internal Medicine

Volumn 263, Issue 5, 2008, Pages 500-505

  Wang, M ^a   Song, W L ^a   Cheng, Y ^a   FitzGerald, G A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 153 Johnson Pavilion ^*  (United States)

Author keywords

Aneurysm; Atherosclerosis; Cardiovascular; Prostacyclin; Prostaglandin; Stroke

Indexed keywords

CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E SYNTHETASE 1 INHIBITOR; PROSTAGLANDIN E2; PROSTAGLANDIN INHIBITOR; UNCLASSIFIED DRUG;

ANALGESIA; AORTA ANEURYSM; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DISEASE PREDISPOSITION; DRUG MECHANISM; HEART PROTECTION; HYPERLIPIDEMIA; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; THROMBOGENESIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; EPOPROSTENOL; FEMALE; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MICE; MICROSOMES; PAIN;

EID: 42149154618     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.01938.x     Document Type: Conference Paper

References (37)

1. Funk C. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001 294 : 1871 5.
2. Burke A, Smyth E, FitzGerald GA. Analgesic-anti-pyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In : Goodman & Gilman's. The Pharmacological Basis of Therapeutics. New York : McGraw-Hill, 2005 673 715.
3. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006 116 : 4 15.
4. FitzGerald GA. COX-2 in play at the AHA and the FDA. Trends Pharmacol Sci 2007 28 : 303 7.
5. Samuellsson B, Morganstern R, Jakobsson PJ. Membrane prostaglandin e synthase-1: a novel therapeutic target. Pharmacol Rev 2007 59 : 207 24.
6. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, FitzGerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest 2006 116 : 1391 9.
7. Qi Z, Hao CM, Langenbach RI et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 2002 110 : 61 9.
8. Francois H, Facemire C, Kumar A, Audoly L, Koller B, Coffman T. Role of microsomal prostaglandin E synthase 1 in the kidney. J Am Soc Nephrol 2007 18 : 1466 75.
9. Wang M, Lee E, Song W et al. Deletion of microsomal PGE synthase-1 protects against oxidant stress and aneurysm formation in hyperlipidemic mice. Circulation 2008 Epub 19 February 2008.
10. Jia Z, Zhang A, Zhang H, Dong Z, Yang T. Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion. Circ Res 2006 99 : 1243 51.
11. Kobayashi T, Tahara Y, Matsumoto M et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004 114 : 784 94.
12. Egan KM, Lawson JA, Fries S et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 2004 306 : 1954 7.
13. Kerr DJ, Dunn JA, Langman MJ et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007 357 : 360 9.
14. Egan KM, Wang M, Fries S et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005 111 : 334 42.
15. Wang M, Zukas AM, Hui Y, Riciotti E, Pure E, FitzGerald GA. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A 2006 103 : 14507 12.
16. Reilly IA, Doran JB, Smith B, FitzGerald GA. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation 1986 73 : 1300 9.
17. Pratico D, Cyrus T, Li H, FitzGerald GA. Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 2000 96 : 3823 6.
18. Kennedy CR, Zhang Y, Brandon S et al. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 1999 5 : 217 20.
19. Hristovska AM, Rasmussen LE, Hansen PB et al. Prostaglandin E2 induces vascular relaxation by E-prostanoid 4 receptor-mediated activation of endothelial nitric oxide synthase. Hypertension 2007 50 : 525 30.
20. Trebino CE, Eskra JD, Wachtman TS, Perez JR, Carty TJ, Audoly LP. Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages. J Biol Chem 2005 280 : 16579 85.
21. Zhuang H, Pin X, Li S, Dore S. Regulation of heme oxygenase expression by cyclopentenone prostaglandins. Exp Biol Med 2003 228 : 499 505.
22. Ikeda-Matsuo Y, Ota A, Fukada T, Uematsu S, Akira S, Sasaki Y. Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury. Proc Natl Acad Sci U S A 2006 103 : 11790 5.
23. Pini B, Grosser T, Lawson JA, Price TS, Pack MA, FitzGerald GA. Prostaglandin E synthases in zebrafish. Arterioscler Thromb Vasc Biol 2005 25 : 315 20.
24. Schneider A, Zhang Y, Zhang M et al. Membrane-associated PGE synthase-1 (mPGES-1) is coexpressed with both COX-1 and COX-2 in the kidney. Kidney Int 2004 65 : 1205 13.
25. Camacho M, Gerboles E, Escudero JR, Anton R, Garcia-Moll X, Villa L. Microsomal prostaglandin E synthase-1, which is not coupled to a particular cyclooxygenase isoenzyme, is essential for prostaglandin E(2) biosynthesis in vascular smooth muscle cells. J Thromb Haemost 2007 5 : 1411 9.
26. Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007 6 : 313 25.
27. Kostenis E, Ulven T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med 2006 12 : 148 58.
28. Huang ZL, Urade Y, Hayaishi O. Prostaglandins and adenosine in the regulation of sleep and wakefulness. Curr Opin Pharmacol 2007 7 : 33 8.
29. Scholich K, Geisslinger G. Is mPGES-1 a promising target for pain therapy? Trends Pharmacol Sci 2006 27 : 399 401.
30. Moriyama T, Highashi T, Togashi K et al. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 2005 1 : 3.
31. Pulchino AM, Rowland S, Wu T et al. Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis. J Pharmacol Exp Ther 2006 319 : 1043 50.
32. Honda T, Segi-Neshida E, Miyachi Y, Narumiya S. Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J Exp Med 2006 203 : 325 35.
33. 2 receptors. Pharmacogenet Genomics 2007 17 : 221 7.
34. Gudis K, Tatsuguchi A, Wada K et al. Clinical significance of prostaglandin E synthase expression in gastric cancer tissue. Hum Pathol 2007 38 : 1826 35.
35. van Heeckeren WJ, Sanborn SL, Narayan A et al. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol 2007 14 : 468 80.
36. Hoshino T, Nakaya T, Homan T et al. Involvement of prostaglandin E2 in production of amyloid-beta peptides both in vitro and in vivo. J Biol Chem 2007 282 : 32676 88.
37. Weggen S, Rogers M, Ertiksen J. NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends Pharmacol Sci 2007 28 : 536 43.